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The Marfan syndrome (MFS) is a heritable connective 
tissue disorder manifested by defects in the skeletal, 
ocular, and cardiovascular systems. It is inherited as an 
autosomal dominant trait, with an incidence of nearly 
one per 10,000 population without gender or ethnic 
predilection. About 30% of MFS cases are sporadic, 
representing new dominant mutations. Although 
diagnostic criteria may be met, intra- and inter-famil­
ial variability in syndromic expression can be quite 
marked. Life expectancy is significantly reduced, and 
more than 85% of patients die of cardiovascular com­
plications. 
Elastin-associated microfibrils are classically identi­
fied by a 10 -12 nm cross-sectional diameter and close 
association with amorphous elastin. Characteristi­
cally, these microfibrils are seen as a fringe surround­
ing elastin cores. Despite their name, these fibrils are 
frequently localized in tissues not associated with elas-
T he Marfan syndrome (MFS) is an autosomal-domi­nant, heritable connective-tissue disorder. It is charac­terized by variable pleiotropic manifestations primar­ily in the skeletal, ocular, and cardiovascular systems. It is now known that defects in fibrillin, an elastin-as­
sociated microfibrillar glycoprotein, cause MFS. Below is a descrip­
tion of the clinical features of MFS and the role skin and dermal 
fibroblasts have played, and continue to play, in the elucidation of 
the basic defect, in the establishment of a molecular nosology, and as 
an aid in the diagnosis of equivocal cases. 
CLINICAL FEATURES 
Skeletal Skeletal features are characterized by a typical body hab­
itus that includes dolichostenomelia and arachnodactyly [1]. Thus, 
skeletal disproportion are useful diagnostic indicators. For example, 
individuals with MFS have long extremities; therefore, the mea­
surement of their lower segment (pubis to sole) is often character­
ized in excess of their upper segment (pubis to vertex). Additionally, 
their arm span (fingertip to fingertip) exceeds their height. Spinal 
scoliosis or kyphoscoliosis is seen in a majority of MFS patients, 
although this finding is less specific than skeletal disproportion [2]. 
Chest deformities, either pectus excavatum or carinatum, are ob­
served in about two-thirds of affected individuals. Other skeletal 
findings include pes planus, joint laxity and hypermobility, and 
recurrent joint dislocation [1]. 
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tin. One of the major and best characterized microfi­
brillar proteins is the glycoprotein, fibrOOn. Fibrillin 
is rich in cysteine residues and thus, extensively intra­
chain disulfide bonded. Defects in fibrillin are now 
known to cause the variable and pleiotropic manifesta­
tions ofMFS. 
Immunofluorescence studies of skin sections and 
dermal fibroblast cultures were the first to show this 
association. The cloning and sequencing of the entire 
fibrillin coding region has enabled the identification 
of the myriad of mutations that cause MFS. Identifica­
tion of the molecular lesions covering the gamut of 
MFS clinical variability should allow the construction 
of genotype/phenotype correlations. It is hoped that 
once available, they may become of prognostic value in 
the clinical management of MFS. Key words: jib,;llin/ 
heritable connective tissue disorders/jibroblasts/mutations. J 
Invest DermatoI10J:S8S-62S, 1994 
ocular The hallmark of ocular involvement in MFS is the occur­
rence of ectopia lentis [3]. The zonular fibers often appear redun­
dant, attenuated, and broken when visualized with the slit lamp and 
the lens is usually dislocated upwards [3,4]. Patients with dislocated 
lenses may be at an increased risk for retinal detachment. Patients are 
also frequently myopic, even if no ectopia lentis is present. Impor­
tantly, ectopia lentis occurs in about 60% of MFS patients, but is 
highly consistent with families [3]. 
Cardiovascular By far the cause of most morbidity and mortality 
in MFS is structural abnormalities of the cardiovascular system [1]. 
The most common defects are aortic root dilatation, mitral valve 
prolapse, and aortic regurgitation [5-8]. Aortic dissection is a com­
mon finding in MFS; in fact, MFS is the leading cause of dissecting 
aneurysm in people under 40 years of age. Aortic regurgitation is 
usually progressive and, thus, uncommon in childhood and more 
frequent during adulthood. Mitral valve prolapse is seen in up to 
three-fourths of individuals with MFS. Chordae tendineae are often 
redundant resulting in mitral regurgitation. MFS patients with mi­
tral valve prolapse with regurgitation are susceptible to bacterial 
endocarditis often affecting the mitral valve. Mitral valve prolapse is 
relatively frequent in the general population [9]; therefore, this 
finding alone is not sufficient for clinical diagnosis. An autosomal­
dominant inheritance of mitral valve prolapse has also been de­
scribed, and those patients often engender clinic:il. confusion with 
MFS [10]. Other congenital cardiac anomalies have also been re­
ported in patients with MFS, but probably represent chance occur­
rences [1]. 
Other Because the protein that is defective in MFS is found in 
areas outside the skeletal, ocular, and cardiovascular systems, mani-
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festations in other areas have also been observed. The only major 
manifestation that occurs outside these systems is dural ectasia [11]. 
Although not symptomatic, dural ectasia may be a useful diagnostic 
tool. 
The most common pulmonary complication in MFS is spontane­
ous pneumothorax, which is seen in about 5% of ratients [12]. 
Apical bullae are also seen and probably predispose patients to spon­
taneous pneumothorax. Femoral hernias are also a frequent co�pl.
i­
cation in MFS, but primarily in affected men. Cutaneous stnae m 
pectoral areas and over the thighs are frequently observed in MFS 
patients [13]. 
MEDICAL MANAGEMENT 
The prognosis of individuals with MFS is variable. Life expectancy 
with little or no medical treatment is reduced to about one-half to 
two-thirds normal, primarily due to cardiovascular complications. 
Well-managed medical treatment, as a coordinated effort from sev­
eral specialties, can significantly prolong life. Indeed, many affected 
individuals lead long, active, and productive lives. 
The most common treatable orthopedic complication in MFS is 
scoliosis [8]. Good results have been obtained using various surgical 
approaches. Repair of pectus deformities, usually for cosmetic pur­
poses , has a good rate of success, but surgery should �wait ske�etal 
maturity. Some surgeons prefer to perform cardiac mterventlOns 
with pectus repair [1]. . . . Cardiovascular defects cause most of the morbidity and mortahty 
associated with MFS [1]. Therefore, careful monitoring, including, 
at least, annual echocardiogram is warranted. Death in MFS patients 
is most often due to aortic root disease manifested by either progres­
sive dilatation resulting in aortic regurgitation, or aortic dissection, 
aneurysm , and rupture. The physical activity of MFS patients 
should be geared away from contact sports, weight lifting, scuba 
diving, and competitive athletics and towards walking, biking, and 
swimming. The use of p-adrenergic blockade has become common­
place in the management of MFS patients, although protection 
from aortic failure (dissection, rupture) is not necessarily assured [1]. 
Prophylactic composite valve graft or aortic or mitral valve replace­
ment are common procedures for MFS patients [14 - 17]. The aortic 
diameter is often a gauge used by surgeons to electively replace 
diseased segments of the aorta. Patients with mitral involvement or 
with composite grafts require prophylactic antibiotic treatment 
prior to dental procedures or other high-risk operations to prevent 
bacterial endocarditis [18]. 
Affected women who become pregnant have, not only the inher­
ent risk of passing the disease to their offspring, but may be at 
considerable risk themselves depending on their cardiovascular 
status. Women with significant valvular or aortic disease are at 
greatest risk, whereas those with few cardiac findings generally 
have uneventful pregnancies [19]. Management of pregnant women 
with MFS includes echo cardiograms throughout pregnancy and 
reducing cardiovascular stress during labor and delivery [19]. 
Regular ophthalmologic examination is a routine part of weff­
m:Jn:lged C:lre for MFS patients. Corrections for myopia :lre 
achieved by conventional means. The ocular haJImark is ectopia 
lentis, however, removal of the lens is not usually necessary, unless 
acceptable visual acuity cannot be obtained [1]. 
ELASTIN-ASSOCIATED MICROFlBRILS 
Elastin-associated microfibrils are identified by their characteristic 
diameter, 10-12 nm, and when observed by electron microscopy, 
they appear as linear bundles [20]. Despite the name, these fibrils are 
often found in tissues not associated with elastin. Thus, ciliary zon­
ules (suspensory ligaments) of the lens have the electron micro­
scopic appearance of micronbrils, although no amorphous elastin is 
observed; immunoreactivity studies have demonstrated identity 
witn e\a�tln.-a""Qclate� mlCIon.nrlh \'2\). Mlcron.nrlls ate wl�ely 
distributed in human tissues , and are believed to form the scaffold­
ing upon which amorphous elastin is deposited [22,23]. Immunolo­
calization studies have shown microfibrils in skin, tendon, cartilage, 
muscle, kidney, perichondrium, periosteum, blood vessels, pleura, 
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Figure 1. Diagrammatic representation of the largest structural re­
gion of the fibrillin eDNA. A, this region extends for 2240 amino acids 
and is composed of 49 cysteine-rich repeats encoded by exons 11- 63 
(adapted from Pereira et al [30]). Rectangles represent precursor calcium bind­
ing EGF-like repeats; ovals represent TGF-bp-like repeats; and the diamond 
represents a novel, mixed motif. B, Composite representation of point muta­
tions that have been found in some of the 43 fibrillin-precursor calcium­
binding EGF-like domains. The always invariant cysteines (shaded circles) are 
disulfide bonded as illustrated by the solid lines. Other usually invariant 
amino acids are identified by one letter codes in representative circles. Note 
that most amino acid substitutions are for the cysteines or other invariant 
amino acids. The other changes noted are non-conservative changes that 
could disrupt folding of that domain. Amino acid positions are according to 
the full length sequence of Pereira et al [30]. C, Representation of fibrillin 
cDNA as in A. Empty areas depict the mis-spliced or deleted exons seen in 
cases of the Marfan syndrome. (See text for details.) 
dura mater, and ciliary zonule [22). Therefore, microfibrils are 
found in tissues in which the pleiotropic features of MFS are ob­
served. 
Probably the most well-characterized microfibrillar component 
is the glycoprotein fibrillin. Fibrillin is 350 kd in molecular weight, 
rich in cysteine residues, and, thus, extensively disulfide bonded 
[24]. It is synthesized by fibroblasts, smooth muscle ceIJs, and proba-
bly other cell types. Among the other elastin-associated microfibril­
lar proteins are microfibril associated glycoproteins (MAGP) that 
have been examined at both biochemical and molecular levels [25-
27). In addition, three fibrillin-like genes have also been found, one 
on chromosome 5, another on chromosome 17 [28] , and, recently, 
fibrillin-like protein. * Interestingly, the fibrillin-like gene on chro­
mosome 5 has been linked to the connective tissue disorder, con­
genital contractural arachnodactyly, which shares some of the phe­
notypic features of MFS [28,29]. However, nothing is currently 
known about their expression and tissue distribution and character­
isti.cs of the \lroteim encQded. 
The complete primary structure and gene organization of fibril­
lin has recently been determined [30) (see Fig 1). Fibrillin is en­
cQnen ny a 'E,ene o£ approximately \ lG kn ln size. Its 65 exons, 75% 
• Gibson MA , Davis E, Filliaggi M, Mecham RP: Identification and par­
tial characterization of a new fibrillin-like protein (FLP) (abstr). Am] Med 
Genet 47:148,1993. 
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Figure 2. Immunoftuorescence staining of 14 micron skin cryosec­
tioDS with monoclonal antibodies to fibrillin. Secondary antibodies 
were conjugated to phycoerythrin. Cells were visualized using the nuclear 
dye. propidium iodide. Photomicrographs were taken on an Olympus BH-2 
fluorescence microscope at standard field of view and exposure time on 
Ektachrome 400 (Kodak) film. A and B show the papillary dermis. respec­
tively. from an age-matched control subject and individual with MFS. There 
is a marked decrease in immunofluorescence at the dermal-epidermaljunc­
tion in the MFS patient when compared to control. Scale bar, 10 p.m. 
of which are homologous to either epidermal growth factor (EGF) 
or transforming growth factor B-binding protein (TGFB-bp) do­
mains, give rise to a 10-kb mRNA. The elucidation of the entire 
fibrillin gene will permit the characterization of all MFS mutations 
and provide a greater understanding of the role fibrillin and its 
domains play in the structural integrity of the extracellular matrix. 
FlBRILLIN IMMUNOFLUORESCENCE 
Immunochemical studies on skin and dermal fibroblast cultures 
were the first to demonstrate the possible etiologic role for fibrillin 
in MFS. In three separate studies. monoclonal antibodies to fibrillin 
showed reduced immunostaining at the dermal/ epidermal junction 
and in the dermis of skin sections from individuals with MFS when 
compared to age-matched controls (Fig 2). Fibroblast cultures also 
demonstrated a reduced apparent accumulation of immunostainable 
fibrils in MFS patients compared to controls (Fig 3) [31-33]. Im-
Figure 3. Immunoftuorescence staining of conftuent fibroblast 
multilayers with antibodies to fibrillin. Control (A) and MFS patient 
(B) cell cultures were established by seeding 2.5 X 105 cells in each chamber 
of a four chamber slide (Nunc). Following a 2-d culture, the slides were 
processed identically to skin sections as described in the legend to Fig 2. 
There is an appreciable decrease in immunostainable fibrils in the MFS 
patient (B) when compared to age matched control (A). Scale bar, 10 p.m. 
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portantly. the immuno£l.uorenscence abnormalities co-segregated 
with the MFS phenotype in affected families. Figure 2 demon­
strates fibrillin immunostaining in skin sections. A is skin from an 
age-matched control subject, andB is skin from a person with MFS. 
It is readily apparent that the intensity of immunostaining in the 
patient sample (B) is greatly reduced when compared to control 
(A). This staining pattern was observed in approximately 70% of 
individuals with unequivocal , clinically diagnosed MFS [31]. Like­
wise, immunostaining of hypercon£l.uent fibroblast cultures (Fig 3) 
showed an apparent decrease in immunostainable fibrils (B) when 
compared to fibroblasts from age-matched controls (A). These im­
munostaining results were observed in about 90% of individuals 
with MFS [31]. In the same study, one quarter of patients in a group 
with other connective tissue disorders also exhibit the same microfi­
brillar abnormalities [31]. More importantly, however, none of the 
disorders in this latter could be confused clinically with MFS. Pa­
tients with mitral valve prolapse syndrome and annuloaortic ectasia 
who have some of the cardiovascular manifestations of MFS, but no 
skeletal or ocular involvement, had normal immunofluorescence 
findings. 
Biochemical abnormalities of synthesis and secretion of fibrillin 
in MFS patients confirmed the immunofluorescence findings [34]. 
Metabolic labeling of fibrillin with 35S-cysteine identified four sub­
groups of MFS patients. In the first, synthesis of fibrillin was de­
creased by about half of normal when compared to control individ­
uals or unaffected family members. The second group synthesized 
normal amounts of fibrillin, but had decreased efficiency of secre­
tion. The third group of patients synthesized and secreted fibrillin 
normally, but the accumulation of fibrils in the extracellular matrix 
was judged to be defective. The fourth group comprised patients in 
whom no abnormalities were found. Although no correlations be­
tween these biochemical analyses and immuno£l.uorescence studies 
have been made, it is important to note that in both types of studies, 
specific abnormalities were seen to segregate with the MFS pheno­
type in families. 
A possible subtype of MFS is the so-called neonatal Marfan syn­
drome (nMFS) that has also been referred to in the literature as 
infantile or congenital Marfan syndrome [35-38]. In contrast to 
classical MFS, patients with nMFS have acute multivalvular cardiac 
disease and die of congestive heart failure within the first year oflife. 
Immunofluorescence analysis of fibrillin from fibroblast cultures 
from eleven patients with nMFS has shown abnormalities in the 
morphology of the immunostained fibrils in nMFS fibroblasts when 
compared to fibroblast cultures from both control individuals and 
classical MFS patients. Specifically, the nMFS fibrils appeared short, 
fragmented, and frayed, these characteristics are not seen together in 
classical MFS patients [39]. t 
To date there are no tests to unequivocally diagnose MFS. In fact, 
diagnosis of MFS is based on a constellation of phenotypic features 
and clinical judgement. In familial cases, linkage analysis or, once 
the fibrillin mutation has been identified, the presence of a specific 
molecular lesion, can help to include or exclude a diagnosis of MFS. 
These analyses are also useful for prenatal or presymptomatic diag­
nosis. In fact, the first prenatal diagnosis in MFS using molecular 
analyses has recently been described [40]. About one-third of MFS 
cases are sporadic and, thus, due to new dominant mutations. 
The.refore, direct aualysis of fibrillin, for possible presence of a 
mutation, would be the only feasible molecular study. Since the 
fibrillin message is about 10 kb in length, and the fact that most, if 
not all, families and patients will have unique mutations, the rapid­
ity of present screening techniques is not optimal to aid in the 
diagnosis of equivocal cases ofMFs. In addition to the costly medi­
cal ramifications of a MFS diagnosis, the issue of a patient's future 
insurability is prime in the clinician's mind, especially in individuals 
where the diagnosis is unclear. 
The availability of the immunofluorescence studies described 
above has precipitated numerous requests by clinicians for fibrillin 
t Godfrey M. et al: Abnormal fibrillin morphology in fibroblast cultures 
from patients with neonatal marfan syndrome (submitted for publication). 
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assay as an aid in the diagnosis of MFS in cases where clinical fea­
tures alone are insufficient or incomplete to permit unequivocal 
diagnosis. The consistency and dependability of our results hold 
promise as an additional tool for the clinician to use.:j: Currently, 
however, although fibrillin immunofluorescence analyses can serve 
as a useful adjunct, MFS remains a clinical diagnosis. 
MOLECULAR DEFECTS IN MFS 
Most mutations currently known to cause MFS are single base 
changes.§ Amino acid substitutions causing MFS have been docu­
mented within fibrillin EGF-like domains [41-44] (Fig IB). In 
addition, four cases in which at least one fibrillin exon has hee'n 
deleted, have been identified (Fig Ie). Three instances wete in 
cases of classical MFS [40,43,45], and one, a patient with the neona­
tal form of MFS. � In one family, a genomic deletion resulted in the 
absence of three EGF-like exons (exons 60-62 [30]) in one allele 
[43]. This mutation caused the production of a shortened polypep­
tide. A second deletion of an EGF-like exon (exon 47 [30]) was due 
to exon skipping caused by a donor splice site mutation [40]. Inter­
estingly, ectopia lentis was not observed in members of the kindred 
harboring the deletion of the three EGF-like motifs [43] and was 
seen unilaterally in only the proband, of the at-least-four genera­
tion family with the donor splice site mutation that causes skipping 
of an EGF-like exon [40]. 
The production of a shortened fibrillin protein as a result of 
deletion or skipping of EGF-like exons may be envisioned, in some 
instances and regions of fibrillin, to provide enough structural sup­
port in the ciliary zonule, but not, for example, in the skeletal or 
cardiovascular systems. Localized trauma, however, such as a severe 
blow to the eye, could precipitate a dislocated lens. This does not 
imply that all MFS patients without dislocated lenses will have 
deletions ofEGF-like exons' or alternatively, patients in which such 
deletions are observed will not have ectopia lentis. In fact, a family 
with a point mutation in an EGF-like exon without ectopia lentis 
has already been described [42]. An additional deletion mutation 
was one caused by the de-novo appearance of a stop codon in an 
exon causing it to be mis-spliced [45J. In that case the exon (exon 51 
[30]) makes up the 3' portion of the final TGFp bp motif in fibrillin. 
Therefore, most of the domain is present, but a region containing 
one of the invariant cysteines, is deleted. 
The three deletions or mis-splicings noted above [40,43,45] occur 
toward the 3' end of the gene. All of those patients and families had 
classical MFS with its variable and pleiotropic manifestations. The 
deletion of the three EGF-like domains occurs in the last and the 
skipping of an EGF-like motif caused by a donor splice site mutation 
occurs in the penultimate of seven EGF-like calcium binding multi­
repeat units. Additionally, the mis-splicing of the TGFp bp exon 
occurs between the penultimate and last of the multi-repeat EGF 
units [30]. Contrary to the clustering of these mutations, the accep­
tor splice site mutation that causes mis-splicing of another EGF-like 
exon, in a patient with the neonatal form of MFS, it occurs in the 
central region of the fibrillin mRNA. � In that case, the deleted exon 
(exon 32 [30]) is located in the largest of the multi-repeat EGF units 
(eighth of twelve exons). Thus, the more severe disease, caused by 
the deletion of this exon, greatly reduced the structural integrity of 
fibrillin and compatibility with life. The increased severity of dis­
ease caused by this fibrillin mutation may be due to its physical 
location or the relative repositioning of a glycosylation site. 
The elucidation of fibrillin mutations in MFS patients spanning 
the spectrum of the variable and pleiotropic phenotypic expression, 
will enable the construction of genotype/phenotype correlations. 
This information, along with fibrillin immunofluorescence and 
* Clericuzio CL, Godfrey M, Olney AH: Fibrillin immunofluorescence 
studies in equivocal Madan syndrome from basic defect to clinical applica­
tion {abstr}. 14th Annual David W. Smith Workshop on Morphogenesis 
and Malformations. Mont-Tremblant, Canada August 12-17, 1993. 
§ Dietz, HC: Madan Syndrome and Related Disorders Research Consor­
tium {personal communication}. 
� Godfrey M et al {submitted for publication}. 
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biochemical analyses, may become useful prognostic indicators and 
aid in the clinical management of the Marfan syndrome. 
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